Speaker: Ursula Theuretzbacher, CEFAIA (Austria)

Moderator: Prabhavathi Fernandes, Chair of GARDP’s Scientific Advisory Committee (USA)

In this webinar, Ursula Theuretzbacher discussed the following aspects of non-traditional antibacterial therapeutics:

• Discovery and early development of “non-traditional” antibacterial approaches is a noticeable trend in the pre-clinical global pipeline
• These approaches include anti-virulence strategies, microbiome-modifying therapies, phages and others such as nanoparticles, immunotherapy and drug-resistance modulation.
• Some of these approaches require novel preclinical efficacy models to predict clinical outcome
• Pathogen-specific or even patient-specific strategies dominate this field
• A major challenge will be to show efficacy in clinical trials

For the Q&A session, Ursula was joined by Laura Piddock (GARDP).

This live webinar including interactive Q&A session was broadcast on 4 February 2020.

If you have questions or comments, please let us know: revive@gardp.org.